NovaBridge Biosciences (NBP) Operating Leases (2019 - 2026)

NovaBridge Biosciences (NBP) has reported Operating Leases for 7 consecutive years, with $2.2 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Operating Leases fell 29.03% year-over-year to $2.2 million; the TTM figure through Dec 2025 stood at $2.2 million (down 29.03% YoY), while the FY2025 annual figure was $2.2 million, down 29.03% from the prior year.
• Operating Leases retreated to $2.2 million in Q4 2025 per NBP's latest filing, from $2.4 million in the prior quarter.
• Across five years, Operating Leases topped out at $12.8 billion in Q4 2021 and bottomed at $2.2 million in Q4 2025.
• Historically, Operating Leases has averaged $987.6 million across 5 years, with a median of $3.1 million in 2024.
• Annual changes were most pronounced in 2021 — Operating Leases soared 1529598.65% — and 2022, when it slumped 99.96%.
• NovaBridge Biosciences' Operating Leases stood at $12.8 billion in 2021, then plunged by 99.96% to $4.5 million in 2022, then jumped by 38.58% to $6.2 million in 2023, then slumped by 50.93% to $3.1 million in 2024, then fell by 29.03% to $2.2 million in 2025.
• Business Quant data shows NBP's Operating Leases at $2.2 million in Q4 2025, $2.4 million in Q3 2025, and $2.6 million in Q2 2025.